Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where E. Thervet is active.

Publication


Featured researches published by E. Thervet.


Kidney International Reports | 2018

Association of a Low-Protein Diet With Slower Progression of CKD

Marie Metzger; Wen Lun Yuan; Jean-Philippe Haymann; Martin Flamant; Pascal Houillier; E. Thervet; Jean-Jacques Boffa; F. Vrtovsnik; Marc Froissart; Lise Bankir; Denis Fouque; Bénédicte Stengel

Introduction Reducing protein intake is recommended for slowing chronic kidney disease (CKD) progression, but assessment of its true effectiveness is sparse. Methods Using the Maroni formula, we assessed dietary protein intake (DPI) from 24-hour urinary urea excretion in 1594 patients (67% men and 33% women) with CKD, 784 of whom also had 7-day food records. Cause-specific hazard ratios (HRs) and 95% confidence intervals for the competing risks of DPI-associated end-stage renal disease (ESRD) or death were estimated in 1412 patients with baseline glomerular filtration rate ≥15 ml/min per 1.73 m2, measured by 51Cr-EDTA renal clearance (mGFR). Results Overall, mean DPI estimated from urea excretion was 1.09 ± 0.30 g/kg of body weight per day (range = 0.34−2.76); 20% of patients had values > 1.3 g/kg per day, and 1.9% had values < 0.6 g/kg per day. Urea excretion and food records produced similar estimates of mean DPI. The lower the mGFR, the lower the mean DPI. Over a median follow-up of 5.6 years, there were 319 ESRD events and 189 pre-ESRD deaths. After adjusting for relevant covariates, each 0.1 g/kg daily higher baseline urea excretion−based DPI or food record−based DPI was associated with an HR for ESRD of 1.05 (95% confidence interval 1.01−1.10) or 1.09 (95% confidence interval 1.04−1.14), respectively. HRs were stronger in patients with baseline mGFR < 30 ml/min per 1.73 m2. There was no association with mortality. The mean age of the patients was 59 ± 15 years, and mean body mass index was 26.6 ± 5.2 kg/m2. Conclusion In this prospective observational study, the lower the baseline DPI, the slower the progression toward ESRD. Most importantly, the absence of threshold for the relation between DPI and ESRD risk indicates that there is no optimal DPI in the range observed in this cohort.


M S-medecine Sciences | 2006

Inhibiteurs de mTOR : Des antiprolifératifs pléiotropiques

Nicolas Pallet; Philippe Beaune; E. Thervet; Christophe Legendre; Dany Anglicheau


Nephrologie & Therapeutique | 2006

Néphrotoxicité du sirolimus : données cliniques et expérimentales

Nicolas Pallet; E. Thervet; Christophe Legendre; Dany Anglicheau


Nephrologie & Therapeutique | 2018

Valeur pronostique du volume extracellulaire au cours de la maladie rénale chronique

A.-L. Faucon; Martin Flamant; Marie Metzger; Jean-Jacques Boffa; Pascal Houillier; E. Thervet; F. Vrtovsnik; Bénédicte Stengel; Emmanuelle Vidal-Petiot; Guillaume Geri


Nephrologie & Therapeutique | 2016

Déterminants de l’hypertension artérielle au cours de la maladie rénale chronique : résultats de la cohorte Nephrotest

Emmanuelle Vidal-Petiot; Marie Metzger; Jean-Jacques Boffa; Jean-Philippe Haymann; E. Thervet; Pascal Houillier; Bénédicte Stengel; F. Vrtovsnik; Martin Flamant


Nephrologie & Therapeutique | 2013

Hémoglobine glycquée (HbA1c), facteur indépendant de mortalité chez des patients non diabétiques présentant une maladie rénale chronique

C. Trivin; Marie Metzger; Jean-Jacques Boffa; F. Vrtovsnik; P. Houiller; Jean-Philippe Haymann; Martin Flamant; Bénédicte Stengel; E. Thervet


Nephrologie & Therapeutique | 2013

Porphyrie aiguë intermittente et maladie rénale chronique : une association méconnue

Alexandre Karras; Nicolas Pallet; C. Schmitt; J.C. Deybach; N. Talbi; E. Thervet; Hervé Puy


Nephrologie & Therapeutique | 2013

Mécanismes et conséquences fonctionnelles de la production rénale d’angiogénine en réponse au stress tissulaire

Iadh Mami; N. Bouvier; S. Pezet; Alexandre Karras; Vannary Meas-Yedid; Philippe Beaune; E. Thervet; Nicolas Pallet


Nephrologie & Therapeutique | 2013

Caractérisation des modifications phénotypiques épithéliales rénales induites par l’acide delta aminolévulinique et le porphobilinogène

Iadh Mami; Alexandre Karras; Hervé Puy; Philippe Beaune; E. Thervet; Nicolas Pallet


Nephrologie & Therapeutique | 2012

Évaluation du risque infectieux après traitement par rituximab en néphrologie

C. Trivin; A. Karras; Bruno Moulin; E. Thervet

Collaboration


Dive into the E. Thervet's collaboration.

Top Co-Authors

Avatar

Nicolas Pallet

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar

Dany Anglicheau

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar

Philippe Beaune

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar

Alexandre Karras

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar

Pascal Houillier

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar

C. Legendre

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar

Christophe Legendre

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bruno Moulin

University of Strasbourg

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge